Compare BioNano Genomics Inc (BNGO) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Starbucks Corp — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while Starbucks Corp trades at $107.37 (market cap $121.00B). The key difference: Starbucks Corp is far larger — about 9166.7× BioNano Genomics Inc's market cap, and Starbucks Corp pays a 2.34% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | SBUX | |
|---|---|---|
Market Cap | $13.20M | $121.00B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.92 | $107.34 |
52-Week Low | $1.09 | $78.46 |
Enterprise Value | $15.81M | $143.69B |
Volume | — | 7,493,833 |
Dividend Yield | — | 2.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Starbucks (SBUX) trades at $107.34, up 1.25% on the day, with a bullish technical signal from moving averages and near the consensus price target of $108.31. Recent Q2 2026 results showed revenue of $9.53B and EPS beat expectations, while the company focuses on cost-cutting through AI initiatives. The stock exhibits strong support at $107 and faces resistance at $108.
The outlook is cautiously optimistic with analyst consensus leaning buy (47.46%), but high P/E of 81.94 and declining net income margins pose valuation concerns. Key risks include execution of AI cost savings and competitive pressures, while dividend growth and loyalty program strength offer stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
